Pamplona
PAMPLONA, Spain, July 7, 2011 -
- ENRY Evaluation in 325 Patients Affirms Efficacy and
Safety of
Radioembolisation in Seriously-ill Patients and
Identifies Specific Populations who may Benefit
From Treatment
Results of the multi-centre European Network on
Radioembolisation with Yttrium-90 Resin Microspheres (ENRY)
analysis of the long-term outcomes related to survival and safety
of radioembolisation using SIR-Spheres in patients with inoperable
primary liver tumours were published on-line today in
Hepatology, the peer-reviewed journal of the American
Association of the Study of Liver
Diseases.[1]
Evaluation of 325 patients with inoperable primary liver cancer
(unresectable hepatocellular carcinoma), who were treated by teams
of liver specialists, oncologists, interventional radiologists and
nuclear medicine physicians at eight centres in Germany, Italy and
Spain, provided "robust evidence of the survival outcomes achieved
with radioembolisation, including patients with advanced disease
and few treatment options," said Bruno Sangro, MD, PhD, Professor
of Hepatology in the Liver Unit of the Clinical University of
Navarra, Pamplona, Spain, and chair of the ENRY group.
PAMPLONA, Spain, October 1, 2010 - "It is increasingly difficult to receive financing and the
financial crisis is weakening investment in R&D+i," said Conny Bogentoft,
Chief Scientific Officer at Karolinska Development AB, during the third and
last plenary session of the 5th International Meeting on Biotechnology,
BioSpain 2010, organised by the Spanish Association of Biocompanies (ASEBIO)
and the Government of Navarre through SODENA.
PAMPLONA, Spain, September 30, 2010 - The global biotechnology industry has been more resistant to
the economic crisis than expected.
PAMPLONA, Spain, September 29, 2010 - The figures regarding BioSpain 2010 have beaten all previous
records, to the extent that it has become the most important event in
biotechnology in southern Europe.
